GlaxoSmithKline has told stock exchanges in Switzerland and the UK that it has increased its shareholding in Addex Pharmaceuticals Ltd to at least 5% of the company’s outstanding capital. The purchases were made by GSK’s investment arm, SR One Ltd, and follow earlier incremental buying in September, 2008.
JADO Technologies GmbH, a closely-held German company specialising in a new type of lipid technology, has raised €3.9 million in a series B financing led by the Berlin-based Peppermint Financial Partners.
Sygnis Pharma AG has raised about €18.3 million with new equity under a long-standing contractual agreement with its two principal shareholders, dievini Hopp BioTech holding GmbH & Co. KG and BASF SE, which will own respectively 36% and 13% of the company.
Santhera Pharmaceuticals of Switzerland has raised a gross CHF 15.9 million in a private share placement with Ares Life Sciences, an investment vehicle controlled by the Bertarelli family.
Apitope International NV, a biopharmaceutical company based in Belgium, has raised €10 million in a series A financing to develop a peptide therapeutic for multiple sclerosis.
Nitec Pharma AG, a Swiss specialty pharmaceutical company, said it has obtained a CHF 24 million (€15.2 million) equity investment from five institutions to finance preparations for the approval and launch of Lodotra, its treatment for rheumatoid arthritis and other inflammatory diseases as well as the development of a product for pain.
GlaxoSmithKline has acquired at least 3% of Addex Pharmaceuticals Ltd through the purchase of shares on the open market.
BTG Plc has announced an all-share offer for Protherics Plc valued at £218.1 million, ending weeks of speculation about the fate of Protherics, a specialty pharmaceutical company.
Intercytex Group of the UK has raised £2.75 million before expenses through a placement of new shares with existing institutional shareholders. The money will be used to finance Phase 3 trials of its lead product for chronic wounds, cyzact.
Investors in SkyePharma Plc will experience a demonstration of the proposition that a slim cut of a big pie is better than a fat cut of a small one.